<DOC>
	<DOCNO>NCT01695174</DOCNO>
	<brief_summary>In current protocol , propose assessment potential beneficial effect antibiotic Xifaxan liver biochemistry , liver relate symptom Mayo risk score 15 adult 5 pediatric patient PSC . Adult patient receive Xifaxan , 550 mg twice daily 12-week period . Pediatric patient PSC whose weight great equal 40 kg receive Xifaxan , 550 mg twice daily .</brief_summary>
	<brief_title>A Pilot Study Xifaxan Treat Patients With PSC</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Inclusion criterion : Diagnosis PSC establish follow criterion : Alkaline phosphatase &gt; 1.5 time upper limit normal least 6 month duration Gammaglutamyl transferase ( GGT ) &gt; 1.5 time upper limit normal pediatric patient Cholangiography demonstrate intrahepatic and/or extrahepatic biliary obstruction , beading , narrow consistent PSC Liver histology past ( available review ) feature consistent diagnostic PSC Both gender Adults : Ages 1875 year . Pediatric : Weight &gt; 40 kg Patient 's informed consent study participation Exclusion criterion : Treatment systematic antibiotic , Azulfidine , ursodeoxycholic acid , corticosteroid , colchicine , methotrexate , azathioprine , cyclosporine , chlorambucil , budesonide , pentoxifylline , tacrolimus , vitamin E prednisone precede three month Active drug alcohol use Prior history allergic reaction antibiotic use study Any condition , opinion investigator , would interfere patient 's ability complete study safely successfully Evidence decompensated liver disease recurrent variceal bleeding , refractory ascites spontaneous hepatic encephalopathy Anticipated need transplantation one year ( Mayo survival model &lt; 80 % oneyear survival without transplant ) Findings highly suggestive liver disease etiology chronic alcoholic liver disease , chronic hepatitis B C infection , hemochromatosis , Wilson 's disease , 1antitrypsin deficiency , nonalcoholic steatohepatitis , primary biliary cirrhosis secondary sclerosing cholangitis Treatment study medication precede three month Pregnancy current lactation ; subject become pregnant study despite precaution withdraw refer primary physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Primary Sclerosing Cholangitis</keyword>
	<keyword>Xifaxan</keyword>
</DOC>